Save time and jump to the most important pieces.
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer
SC 13D - Fresh2 Group Ltd (0001786511) (Subject)
SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
8-K - Fresh2 Group Ltd (0001786511) (Filer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
3 - Fresh2 Group Ltd (0001786511) (Issuer)
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin
PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution
PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace
AnPac Bio-Medical Science (NASDAQ:ANPC) reported quarterly losses of $(0.04) per share. This is a 99.46 percent increase over losses of $(7.40) per share from the same period last year. The company reported $87.00 thousand in sales this quarter. This is a 73.87 percent decrease over sales of $333.00 thousand the same period last year.
Gainers Biotricity (NASDAQ:BTCY) stock rose 30.2% to $0.73 during Tuesday's regular session. Trading volume for Biotricity's stock is 264.8K as of 13:30 EST. This is 121.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $38.3 million. TScan Therapeutics (NASDAQ:TCRX) shares moved upwards by 28.65% to $2.11. As of 13:30 EST, TScan Therapeutics's stock is trading at a volume of 57.1K, which is 136.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.9 million. Immatics (NASDAQ:IMTX) shares rose 26.93% to $9.29. Immatics's stock is trading at a volume of 3.3 million shares a
Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela
NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021. Gross margi